These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24399717)

  • 1. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
    Zaitone SA; Hammad LN; Farag NE
    Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
    Kabel AM; Omar MS; Alhadhrami A; Alharthi SS; Alrobaian MM
    Physiol Behav; 2018 May; 188():108-118. PubMed ID: 29410018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
    Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
    J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R; Marti M; Morari M
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
    Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
    Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
    Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Frouni I; Kwan C; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2139-2144. PubMed ID: 32601846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.
    Thomas B; Saravanan KS; Mohanakumar KP
    Neurochem Int; 2008 May; 52(6):990-1001. PubMed ID: 18164516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
    Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
    Fredriksson A; Danysz W; Quack G; Archer T
    J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
    Liu Q; Zhang S; Zhu D; Tang X; Che Y; Feng X
    Behav Brain Res; 2020 Feb; 379():112337. PubMed ID: 31697983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.